One of the risk factors for severe illness from COVID-19 is diabetes. While scientists aren’t sure why diabetes leads to poorer outcomes for COVID-19 patients, early studies are indicating that controlling blood sugar may be an important component of treatment. Researchers from across the globe have been reporting that blood glucose monitoring and control – through insulin infusion and medication (Metformin) – has been related to better outcomes for patients than those who had uncontrolled hyperglycemia.
To better understand the link between blood glucose and COVID-19, a randomized, controlled clinical study is needed. The University of Minnesota is planning such a clinical trial of the impact of Metformin on both prevention and treatment of COVID-19. Parsemus Foundation has provided seed funding for the project, but additional funders are needed to move this critical study forward. Contact us for more information and see details on our COVID page.